UNSPSC 51203300: Immunosupressant phthalimides

This classification denotes imides of phthalic acid(s), substances called phthalimides, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPRESSANT PHTHALIMIDES.

UNSPSC 51203300 Immunosuppressant phthalimides is a Class code that in recent state and local procurement activity names pharmaceuticals that do not align with the code's nominal scope — the recent opportunities record shows purchases of broad-spectrum antibiotics (Doxycycline Hyclate, Ciprofloxacin Hydrochloride), opioid-reversal agents (Naloxone), and drug deactivation systems, none of which are immunosuppressant phthalimides. State and local purchasing offices appear to be using this code as a catchall pharmaceutical or emergency-response medication tag rather than for its specific immunosuppressive drug class. The issuing bodies soliciting under the code include state departments of public health and county governments, with purchasing vehicles ranging from cooperative-procurement piggyback arrangements (MMCAP Infuse consortium) to direct competitive bidding.

Recent opportunities show activity in Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 contract to Chartwell Rx LLC on August 28, 2026 through an Invitation for Bid process for pharmaceutical warehouse supply via the MMCAP Infuse cooperative vehicle, with an initial 12-month term and renewal options for years 2 and 3. Seminole County, Florida issued an IFB on June 30, 2026 seeking annual purchases of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries, a two-year initial term with one-year renewal option, and potential FEMA funding. The mismatch between the code name and actual procurement suggests that firms pursuing opportunities tagged to this code should verify the specific pharmaceutical line items in each solicitation rather than assuming alignment with immunosuppressant classification.